Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Abiraterone
Drug ID BADD_D00014
Description Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.
Indications and Usage Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.
Marketing Status approved
ATC Code L02BX03
DrugBank ID DB05812
KEGG ID Not Available
MeSH ID C089740
PubChem ID 132971
TTD Drug ID D02STN
NDC Product Code 42291-024; 42291-073; 69238-1754; 60219-1754; 60687-455; 17337-0082; 54893-0070; 30007-838; 69238-1165; 60219-1165
UNII G819A456D0
Synonyms abiraterone | 17-(3-pyridyl)androsta-5,16-dien-3beta-ol | CB-7598 | CB 7598 | CB7598
Chemical Information
Molecular Formula C24H31NO
CAS Registry Number 154229-19-3
SMILES CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lumbar spinal stenosis15.10.04.008; 17.10.03.0040.000334%Not Available
Metastases to bone15.09.03.006; 16.22.02.0050.006440%Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.0150.001001%Not Available
Penile size reduced21.12.01.0180.001135%Not Available
Pernicious anaemia10.04.01.007; 07.17.01.004; 01.03.01.0030.000334%Not Available
Prostate cancer recurrent21.04.02.008; 16.25.01.0050.000501%Not Available
Prostate cancer stage IV16.25.01.007; 21.04.02.0100.000734%Not Available
Small cell carcinoma16.16.01.0170.000501%Not Available
Urinary bladder haemorrhage24.07.01.086; 20.03.01.0230.001635%Not Available
Metastases to bone marrow16.22.02.013; 01.05.01.0220.000667%Not Available
Metastases to meninges16.22.02.003; 17.02.10.0120.000334%Not Available
Neuroendocrine tumour16.24.01.009; 05.08.01.0130.000901%Not Available
Meningorrhagia24.07.04.030; 17.08.01.056; 12.01.10.0160.000501%Not Available
Lymphangiosis carcinomatosa01.09.01.027; 24.09.02.007; 16.22.02.0090.000501%Not Available
Neuroendocrine carcinoma16.24.01.007; 05.08.01.0110.000334%Not Available
Pancreatic carcinoma stage IV16.13.10.005; 07.21.09.0080.000334%Not Available
Hormone-refractory prostate cancer21.04.02.007; 16.25.01.004--Not Available
Sarcopenia15.05.06.0040.000334%Not Available
Spinal pain17.10.01.020; 15.02.01.008; 08.01.08.0300.001235%Not Available
Internal haemorrhage24.07.01.0720.001502%Not Available
Acquired apparent mineralocorticoid excess24.08.04.008; 14.05.01.012; 05.01.01.0080.000501%Not Available
Biliary obstruction09.02.02.0050.000334%Not Available
Dilated cardiomyopathy02.04.01.0170.000501%Not Available
Disease complication08.01.03.0870.000667%Not Available
Gait inability17.02.05.069; 08.01.02.0110.003036%Not Available
Hepatic cytolysis09.01.07.0360.000501%Not Available
Hyperglycaemic hyperosmolar nonketotic syndrome17.02.04.022; 14.07.04.009; 05.07.04.0090.000501%Not Available
Immobilisation syndrome08.01.03.092; 15.03.05.0170.000501%Not Available
Neuroendocrine cancer of the prostate metastatic21.04.02.012; 16.25.01.008; 05.08.01.0190.000334%Not Available
Physical deconditioning08.01.03.0960.000734%Not Available
The 11th Page    First    Pre   11 12    Next   Last    Total 12 Pages